US FDA. DRAFT GUIDANCE. RECOMMENDATIONS FOR EVALUATING DONOR ELIGIBILITY USING INDIVIDUAL RISK-BASED QUESTIONS TO REDUCE THE RISK OF HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION BY BLOOD AND BLOOD PRODUCTS. JAN 2023.